Business
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
- RADR® A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding potential for biopharma
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- RADR® A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding potential for biopharma collaborations\n - Drug candidate LP-184 granted Orphan Drug Designations by the FDA for the treatment of glioblastoma multiforme and pancreatic cancer\n - Preparing to launch multiple human clinical trials in the next several quarters for LP-300, LP-184 and LP-100\n - $73.8 million of cash, cash equivalents and marketable securities as of September 30, 2021\n - Conference call scheduled for 4:30 p.m. ET (Eastern Time) today\n\n\nDALLAS, Nov. 1, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today provided a business update and reported financial results for the third quarter ended September 30, 2021.\n\n \n \n \n \n \n \n\n \n\"Lantern has continued to advance our portfolio, both clinically and in new preclinical indications, as well as rapidly expand our RADR® A.I. platform this past quarter,\" stated Panna Sharma, President & CEO of Lantern Pharma Inc. \"Our A.I. driven approach to oncology drug development will be pivotal in discovering additional indications for our existing compounds, as well as the identification of entirely new drug candidates. Our strong balance sheet with over $73.8 million of cash, cash equivalents and marketable securities as of September 30, 2021 provides us with a solid foundation as we execute on our clinical programs and expand our proprietary RADR® A.I. platform.\"\nThird Quarter 2021 and Subsequent Highlights:\nAchieved over 10 billion data points from highly curated oncology datasets focused on increasing the performance and scale of our A.I. platform, RADR®, for oncology drug development LP-184 granted Orphan Drug Designation for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas by the U.S. Food and Drug Administration (FDA) Announced positive preclinical data in glioblastoma with LP-184 and expanded GBM research collaboration with Johns Hopkins University LP-184 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA Submitted poster presentation on the effectiveness of LP-184 in pancr...